GDC-0152 (RG7419)

Alias: GDC0152; GDC 0152; GDC0152; RG-7419; RG7419; RG 7419
Cat No.:V0052 Purity: ≥98%
GDC-0152 (RG-7419) is a novel and potent antagonist of IAP (inhibitor of apoptosis) family proteins with antitumor activity.
GDC-0152 (RG7419) Chemical Structure CAS No.: 873652-48-3
Product category: IAP
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
2mg
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

GDC-0152 (RG-7419) is a novel and potent antagonist of IAP (inhibitor of apoptosis) family proteins with antitumor activity. In cell-free assays, it inhibits IAPs with Kis of 28 nM, 14 nM, 17 nM, and 43 nM for XIAP-BIR3, ML-IAP-BIR3, cIAP1-BIR3, and cIAP2-BIR3, respectively; it has a lower affinity for cIAP1-BIR2 and cIAP2-BIR2. A Phase 1 clinical trial is looking into GDC-0152 as a potential cancer treatment.

Biological Activity I Assay Protocols (From Reference)
Targets
MLXBIR3SG (Ki = 14 nM); cIAP1-BIR3 (Ki = 17 nM); XIAP-BIR3 (Ki = 28 nM); cIAP2-BIR3 (Ki = 43 nM); XIAP-BIR2 (Ki = 112 nM)
ln Vitro
GDC-0152 can block protein−protein interactions that involve IAP proteins and pro-apoptotic molecules. GDC-0152 is demonstrated to disrupt the association of ML-IAP, cIAP1, and cIAP2 with Smac as well as XIAP binding to partially processed caspase-9 using transiently transfected HEK293T cells. The endogenous association of ML-IAP and Smac is effectively also eliminated by GDC-0152 in melanoma SK-MEL28 cells. When compared to healthy human mammary epithelial cells (HMEC), GDC-0152 had no effect on HMEC but reduced cell viability in the MDA-MB-231 breast cancer cell line. It has been discovered that GDC-0152 activates caspases 3 and 7 in a dose- and time-dependent manner. In A2058 melanoma cells, GDC-0152 has been shown to cause cIAP1 to degrade rapidly. Its affinity for cIAP1 is supported by the fact that it successfully induces cIAP1 degradation at concentrations as low as 10 nM.
ln Vivo
GDC-0152 has moderate predicted hepatic clearance based on metabolic stability assays carried out using human liver microsomes.Over the range of concentrations investigated (0.1–100 μM), plasma protein binding of GDC-0152 is moderate and comparable in mice (88–91%), rats (89–91%), dogs (81–90%), monkeys (76–85%), and humans (75–83%); higher plasma protein binding is observed in rabbits (95–96%). In all tested species, GDC-0152 does not preferentially distribute to red blood cells with blood-plasma partition ratios ranging from 0.6 to 1.1. GDC-0152's pharmacokinetics are achieved with a Cmax of 53.7 μM and an AUC of 203.5 h•μM. [1]
Enzyme Assay
The IAP protein constructs are added to wells containing serial dilutions of the antagonists or the peptide AVPW, as appropriate, and the Hid-FAM probe or AVP-diPhe-FAM probe in the polarization buffer to determine the inhibitory constants (Ki) for the antagonists. After 30 minutes, samples are read. The IC50 values are calculated by fitting the data to a 4-parameter equation using software, and fluorescence polarization values are plotted as a function of antagonist concentration. Based on the IC50 values, the antagonists' Ki values are calculated.
Cell Assay
GDC-0152 is used to treat HMECs and MDA-MB-231 breast cancer cells in the recommended concentrations. The CellTiter-Glo luminescent cell viability assay is used to determine cell death 72 hours after the start of treatment.
Animal Protocol
phosphate-buffered saline; 10, 50, 100 mg/kg; Oral
Human-tumor xenograft mouse models of MDA-MB-231 breast cancer
References

[1]. J Med Chem . 2012 May 10;55(9):4101-13.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C25H34N6O3S
Molecular Weight
498.64
Exact Mass
498.24
Elemental Analysis
C, 60.22; H, 6.87; N, 16.85; O, 9.63; S, 6.43
CAS #
873652-48-3
Appearance
Solid powder
SMILES
C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=NS3)C4=CC=CC=C4)NC
InChi Key
WZRFLSDVFPIXOV-LRQRDZAKSA-N
InChi Code
InChI=1S/C25H34N6O3S/c1-16(26-2)22(32)27-21(18-12-7-4-8-13-18)25(34)31-15-9-14-19(31)23(33)28-24-20(29-30-35-24)17-10-5-3-6-11-17/h3,5-6,10-11,16,18-19,21,26H,4,7-9,12-15H2,1-2H3,(H,27,32)(H,28,33)/t16-,19-,21-/m0/s1
Chemical Name
(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-(4-phenylthiadiazol-5-yl)pyrrolidine-2-carboxamide
Synonyms
GDC0152; GDC 0152; GDC0152; RG-7419; RG7419; RG 7419
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~99 mg/mL (~198.5 mM)
Water: ~3 mg/mL (~6.0 mM)
Ethanol: ~99 mg/mL (~198.5 mM)
Solubility (In Vivo)
30%Propylene glycol, 5%Tween 80, 65% D5W: 5mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0055 mL 10.0273 mL 20.0545 mL
5 mM 0.4011 mL 2.0055 mL 4.0109 mL
10 mM 0.2005 mL 1.0027 mL 2.0055 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00977067 Terminated Drug: GDC-0152 Solid Cancers Genentech, Inc. June 2007 Phase 1
Biological Data
  • GDC-0152

  • GDC-0152

  • GDC-0152

    Flygare JA, et al. J Med Chem, 2012, 55(9), 4101-4113.
Contact Us